MedTrace Logo

A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.

NCT06015048 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 364

Last updated 2024-08-05

No results posted yet for this study

Summary

The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A1811 combined with other antitumor therapies in advanced solid tumors. To explore the reasonable dosage of SHR-A1811 combined with other antitumor therapies for advanced solid tumors.

Conditions

  • HER2-expressing Advanced Solid Tumors

Interventions

DRUG

SHR-A1811 combined with Pyrotinib.

SHR-A1811 combined with Pyrotinib

DRUG

SHR-A1811 combined with other antitumor therapies

SHR-A1811 combined with other antitumor therapies

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-11
Primary Completion
2026-11-30
Completion
2026-12-29

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06015048 on ClinicalTrials.gov